121 related articles for article (PubMed ID: 26937212)
1. CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.
Liu X; Chong Y; Liu H; Han Y; Niu M
Korean J Physiol Pharmacol; 2016 Mar; 20(2):161-8. PubMed ID: 26937212
[TBL] [Abstract][Full Text] [Related]
2. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract][Full Text] [Related]
3. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract][Full Text] [Related]
4. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.
Liu X; Chong Y; Tu Y; Liu N; Yue C; Qi Z; Liu H; Yao Y; Liu H; Gao S; Niu M; Yu R
J Hematol Oncol; 2016 Oct; 9(1):108. PubMed ID: 27733172
[TBL] [Abstract][Full Text] [Related]
5. Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.
Liu X; Tu Y; Wang Y; Zhou D; Chong Y; Shi L; Liu G; Zhang X; Wu S; Li H; Gao S; Niu M; Yu R
Cancer Cell Int; 2020; 20():97. PubMed ID: 32256206
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathway.
Shan Q; Li S; Cao Q; Yue C; Niu M; Chen X; Shi L; Li H; Gao S; Liang J; Yu R; Liu X
Korean J Physiol Pharmacol; 2020 May; 24(3):193-201. PubMed ID: 32392910
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy.
Gao W; Lu C; Chen L; Keohavong P
J Thorac Oncol; 2015 May; 10(5):815-825. PubMed ID: 25629636
[TBL] [Abstract][Full Text] [Related]
8. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity.
Niu M; Xu X; Shen Y; Yao Y; Qiao J; Zhu F; Zeng L; Liu X; Xu K
Chem Biol Interact; 2015 Jul; 237():66-72. PubMed ID: 26026911
[TBL] [Abstract][Full Text] [Related]
9. CRM1-mediated nuclear export of proteins and drug resistance in cancer.
Turner JG; Sullivan DM
Curr Med Chem; 2008; 15(26):2648-55. PubMed ID: 18991627
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer.
Wang Y; Wang Y; Xiang J; Ji F; Deng Y; Tang C; Yang S; Xi Q; Liu R; Di W
Cancer Lett; 2014 Feb; 343(1):6-13. PubMed ID: 24018641
[TBL] [Abstract][Full Text] [Related]
11. A role for RanBP1 in the release of CRM1 from the nuclear pore complex in a terminal step of nuclear export.
Kehlenbach RH; Dickmanns A; Kehlenbach A; Guan T; Gerace L
J Cell Biol; 1999 May; 145(4):645-57. PubMed ID: 10330396
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
13. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
14. Involvement of CRM1, a nuclear export receptor, in mRNA export in mammalian cells and fission yeast.
Watanabe M; Fukuda M; Yoshida M; Yanagida M; Nishida E
Genes Cells; 1999 May; 4(5):291-7. PubMed ID: 10421839
[TBL] [Abstract][Full Text] [Related]
15. Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells.
Xu J; Wu S; Li G
Exp Ther Med; 2023 Jul; 26(1):326. PubMed ID: 37346402
[TBL] [Abstract][Full Text] [Related]
16. CRM1-dependent, but not ARE-mediated, nuclear export of IFN-alpha1 mRNA.
Kimura T; Hashimoto I; Nagase T; Fujisawa J
J Cell Sci; 2004 May; 117(Pt 11):2259-70. PubMed ID: 15126627
[TBL] [Abstract][Full Text] [Related]
17. Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1.
Yang J; Bardes ES; Moore JD; Brennan J; Powers MA; Kornbluth S
Genes Dev; 1998 Jul; 12(14):2131-43. PubMed ID: 9679058
[TBL] [Abstract][Full Text] [Related]
18. Small Molecule Inhibitors of CRM1.
Ferreira BI; Cautain B; Grenho I; Link W
Front Pharmacol; 2020; 11():625. PubMed ID: 32574233
[TBL] [Abstract][Full Text] [Related]
19. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma.
van der Watt PJ; Zemanay W; Govender D; Hendricks DT; Parker MI; Leaner VD
Oncol Rep; 2014 Aug; 32(2):730-8. PubMed ID: 24898882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
